Fig. 1 | Leukemia

Fig. 1

From: Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

Fig. 1

Weighted Kaplan–Meier curves of progression-free survival (a) and overall survival (b) in all patients according to treatment (DA-EPOCH-R or R-CHOP); Weighted Kaplan–Meier curves of progression-free survival (c) and overall survival (d) according to treatment in patients younger than 65 years. Weighted Kaplan–Meier estimates of progression-free survival according to biology (DE patients with cytogenetic alteration such as SH, DH/TH, or atypical DH defined as “other” vs patients without any abnormalities defined as “DE-only”) and treatment (e)

Back to article page